Evaluating the efficacy of enalapril, eplerenone alone, and their combination on proteinuria

Evaluating the efficacy of enalapril, eplerenone alone, and their combination on proteinuria in patients with diabetic nephropathy: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250817066890N1

Enrollment

Registered

2025-08-22

Start date

2025-08-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Group 1 is treated with 25 mg of Eplerenone daily. Intervention 2: Group 2 is treated with 10 mg of Enalapril daily. Intervention 3: Group 3 is treated with a combination therapy of 10

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. UACR =30 mg/g2. HbA1c =8.5%3. DBP 70 ml/min

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Estimated glomerular filtration rate (eGFR). Timepoint: "Before the intervention and 6 months after the start of the intervention". Method of measurement: eGFR will be calculated using the CKD-EPI or MDRD formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayyed Mehdi Rasooli Manesh

Kashan University of Medical Sciences

mehdirasoolimanesh@gmail.com+98 31 5558 9444

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026